SECOND GENERATION VISCO-ELASTIC SOLUTION
INDICATED IN THE TREATMENT OF PAIN IN SMALL JOINTS AFFECTED BY OSTEOARTHRITIS
UNIQUE COMBINATION OF CROSS-LINKED HYALURONIC ACID + MANNITOL
MEDICAL DEVICE – 1 x 1 ml
(SINGLE INTRA-ARTICULAR INJECTION)
HAppyMini® is supplied in a 1ml pre-filled syringe and is entirely appropriate for intra-articular injection into:
TMC joint of the thumb – Fingers – Big toe – Temporomandibular joint – Wrist – Subtalar joint
High Concentration for Prolonged Activity
HAppyMini® contains high concentration of hyaluronic acid: 1.6% i.e. 16 mg/syringe
Cross-Linked Hyaluronic Acid
HAppyMini® is a cross-linked hyaluronic acid gel (IPN-Like technology)
- Ensures a gel-like rheological behaviour, maximizing then the mechanical properties of hyaluronic acid.
- Increases the residence time of the gel in the joint cavity, preventing biodegradation from free radicals and enzymes.
IPN-Like Technology: a unique and patented cross-linking process
Compared to the classic cross-linking technique, the IPN-Like technology, or InterPenetrated Cross-linked Networks, involves combining, inserting one into another, two monophasic hyaluronic acid networks previously purified and cross-linked which are mechanically independent. Interpenetration of Cross-linked Networks:
- Optimizes the density of the chemical bonds while minimizing the use of reticulating agent (BDDE) within the monophasic gel, ensuring a longer-lasting effect of the product.
- Preserves the partial independence of the inter-penetrated networks and guarantees the gel is supple and easy to inject into the joint.
HAppyMini® also contains high concentration of mannitol (35mg/syringe).
Long-lasting effect: Mannitol is an anti-oxidant which protects hyaluronic acid chains from free radicals and limits their degradation, increasing then their residence time in the joint cavity.
Analgesic effect: Due to its free radical scavenging properties, mannitol also ensures local analgesic effect.
Stabilizer: because it is a thermal stabilizer, mannitol allows HAppyCross™ to guarantee a stability of its rheological properties all along its storage.
HAppyMini® is highly purified and results from bacterial fermentation.
HAPPYMINI IN THE TEMPOROMANDIBULAR JOINT
- Treatment of Temporomandibular joint OA with an intra-articular injection of Hyaluronic acid: Predictive factors of patient’s satisfaction 6 months after a single intra-articular injection of HAppyMini. Study conducted on around 50 patients -Presentation displayed at the SFR 2018 congress-
HAPPYMINI IN THE TRAPEZIOMETACARPAL JOINT
- Predictive Factors of Response to a Single Injection of Mannitol-Modified Cross-Linked HA (HANOX-M-XL) in Patients with Trapeziometacarpal Osteoarthritis Results of a Multicentre Prospective Open-Label Pilot Study (Instinct Trial) J. Dauvissat, C. Rizzo, H. Lellouche, J. Porterie, S. Melac-Ducamp, V. Locquet, V. Travers, B. Maillet, T. Conrozier. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders (2018) https://doi.org/10.1177%2F1179544118782901 -Publication-
HAPPYMINI IN THE BIG TOE
- Is the radiological grade a predictive factor of efficacy of an intra-articular injection of hyaluronic acid (HAppyMini) in patients suffering from Hallux rigidus? Prospective survey on around 60 patients treated in private medical care –poster displayed at the ACR 2018 congress-
- Effect of Mannitol on Hyaluronic Acid Stability in Two in Vitro Models of Oxidative Stress. M. Rinaudo; B Lardy; L. Grange; T. Conrozier. Polymers 2014, 6, 1948-1957; doi: 10.3390/polym6071948 -Publication-
- Mannitol preserves the elasto-viscous properties of hyaluronic acid in an in vitro model of oxidative stress. T. Conrozier; P. Mathieu; M. Rinaudo. Rheumatol Ther. 2014; doi: 10.1007/s407444-014-0001-8. -Publication-
- Addition of Mannitol to Hyaluronic Acid may Shorten Viscosupplementation Onset of Action in Patients with Knee Osteoarthritis: Post-Hoc Analysis of A Double-blind, Controlled Trial. Eymard F, Bossert M, Lecurieux R, Maillet B, Chevalier X, et al. (2016) J Clin Exp Orthop 2: 21. doi: 10.4172/2471-8416.100021 – Publication –
- Is the addition of a polyol to hyaluronic acid a significant advance in the treatment of osteoarthritis? Conrozier T. Curr Rheumatol Rev. 2017 Jul 10. doi:10.2174/1573397113666170710115558. -Publication-
- Consensus statement on viscosupplementation with hyaluronic acid for the management of OA. Y. Henrotin; R. Raman; P. Richette; H. Bard, J. Jerosch; T. Conrozier; X. Chevalier; A. Migliore. Semin Arthritis Rheum. 2015 Apr 30. doi: 10.1016/j.semarthrit.2015.04.011. -Publication-
- Steroids, lidocaine and ioxaglic acid modify the viscosity of hyaluronic acid: in vitro study and clinical implications. T. Conrozier; J. Patarin; P. Mathieu; M. Rinaudo. SpringerPlus . 2016;5:170; doi: 10.1186/s40064-016-1762-z. – Publication –
- Decision Algorithms for the Retreatment with Viscosupplementation in Patients Suffering from Knee Osteoarthritis. Recommendations from the EUROpean VIScosupplementation COnsensus Group (EUROVISCO). R. Raman, Y. Henrotin, X. Chevalier, A. Migliore, J. Jerosch, J. Montfort, H. Bard, D. Baron, P. Richette, T. Conrozier. Cartilage. February-01-2017. Doi: 10.1177/1947603517693043 -Publication-